Glumetza generic
Glumetza is an oral medication owned by Santarus Inc. The drug contains the active ingredient metformin hydrochloride. Glumetza was first authorized for market use on 03 June, 2005. The drug is available in tablet, extended-release dosage forms.
When will Glumetza generic be available?
The generic version of Glumetza is expected to be released after the 23rd of March, 2025. This is when the last patent on Glumetza (US7780987 titled 'Controlled release dosage forms') expires.
Glumetza uses
Glumetza is used in the management of type 2 diabetes. It works by reducing glucose production in the liver and increasing insulin sensitivity in the body's cells. This makes it easier for your body to control blood sugar levels.
Glumetza patent expiration
Glumetza is protected by two patents. The first patent (US8323692 titled 'Controlled release dosage forms') expired on the 30th of March, 2023. The remaining patent of Glumetza (US7780987 also titled 'Controlled release dosage forms') is due to expire on the 23rd of March, 2025, opening up the pathway for the release of Glumetza generics. Below are the details of the patent: